3-Deacetoxy-7-(.ALPHA.-amino-1-cyclohexenylacetamido) cephalosporanic acid (SCE-100), a new semisynthetic cephalosporin. I. Comparative in vitro antibacterial activities of SCE-100 and cephalexin (CEX).

Abstract

3-Deacetoxy-7-(.alpha.-amino-1-cyclohexenylacetamido) cephalosporanic acid (SCE-100) has a potent antibacterial activity against gram-positive and gram-negative bacteria. The minimum inhibitory concentration of SCE-100 is 0.2-12.5 .mu.g/ml against gram-positive bacteria including penicillin G-resistant Staphylococcus aureus and 6.25-100 .mu.g/ml against gram-negative bacteria. SCE-100 inhibits clinically isolated strains of penicillin G-resistant S. aureus and ampicillin-resistant Escherichia coli, and the corresponding sensitive strains. The activity of SCE-100 is enhanced by decreasing the inoculum size and is only slightly influenced by medium pH, difference of medium composition and the addition of horse serum. SCE-100 has bactericidal activity against S. aureus and E. coli. There is a stepwise development of in vitro bacterial resistance to SCE-100 by serial transfer of organisms into a liquid medium containing SCE-100. Cross resistance was observed between SCE-100 and other tested cephalosporins.